Likewise, mutations at 19 residues in TET2 are reported at least twice in solid human cancers, which are also reported in myeloid malignancies, with mutations at residues 29, 550, 1516, 1718, and 1762 occurring most frequently in solid tumors (Table 1, Figure 3). This evidence concerns the gene TET2 and myeloid neoplasm.